Novo Nordisk A/S (NVO)
| Market Cap | 301.38B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.14 |
| PE Ratio | 21.72 |
| Forward PE | 17.25 |
| Dividend | $1.30 (1.91%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 6,883,968 |
| Open | 67.51 |
| Previous Close | 68.03 |
| Day's Range | 67.33 - 68.72 |
| 52-Week Range | 66.88 - 148.15 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 141.67 (+107.61%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $141.67, which is an increase of 107.61% from the latest price.
News
Coffers swelling on Wegovy sales, Novo Holdings doubles income and returns in 2024
Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on Wedne...
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, ...
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...
Pharma tariffs the 'number one question' on investors' minds, Barclays says
Emily Field, head of European pharmaceuticals research at Barclays, weighs in on the potential impact of U.S. tariffs on the pharmaceuticals sector.
Novo Nordisk: Finally A Buying Opportunity
Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case for NV...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs a...
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the ...
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to...
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Novo Nordisk sinking on lighter-than-expected GLP-1 demand.
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
Novo Nordisk says compounded drugs are hurting Wegovy sales
CNBC's Karen Gilchrist discusses the impact of U.S. compounded weight loss drugs and potential tariffs on obesity drug giant Novo Nordisk.
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment. "I'm very confiden...
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
Lexicon Pharmaceuticals Inc. LXRX stock is trading higher on Friday.
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2...
Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal
Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting Wegovy sales. CEO Lars Fruergaard Jørgensen told shareholders at its Annual Gen...
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edg...
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “2024 was another y...
Checking in on the weight-loss drug space: Novo Nordisk, Eli Lilly, and others
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons.
Buy Low, Never Sell - 2 Elite Dividend Stocks Built To Last
Markets are rotating away from U.S. stocks, but I'm doubling down on undervalued American companies built to last decades, not chase trends. Political noise and short-term trading dominate headlines, ...
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
SAP Overtakes Novo Nordisk as Europe's Most Valuable Company
The business-software group claimed the top spot as Europe's largest company by market value, dethroning Wegovy maker Novo Nordisk.
Novo Nordisk's $2 billion obesity deal
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss Eli Lilly's latest obesity pill trial.
Novo Nordisk expands discounted Wegovy to all cash-paying US customers
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy.